‘Revolutionary’ liquid sickle cell treatment has been unveiled
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
List view / Grid view
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
1 May 2014 | By Nova Laboratories
UK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
4 December 2013 | By Nova Laboratories
The product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...